Alexza Pharmaceuticals, Inc. announced that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato(R) nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking.

Dutch company to-BBB announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for to-BBB’s brain cancer lead
product 2B3-101.

Celsion Corp.announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program. Under the Fast Track Designation, Celsion is now eligible to submit a U.S. New Drug Application (NDA) on a rolling basis. This permits the FDA to review sections of the NDA in advance of receiving the complete submission.

pSivida Corp. announced that its licensee, Alimera Sciences, Inc. has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien(R) for the treatment diabetic macular edema (DME). With priority review, Alimera could receive a response from the FDA in the fourth quarter regarding its NDA for Iluvien, which was submitted at the end of June 2010.

InSite Vision Inc. announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to treat post-surgical ocular pain and swelling.